Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stupp

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
Neurology|September 2, 2011
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastomaM Weller, T Gorlia, J G Cairncross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2015
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trialN Fazio, R Biffi, R Maibach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiformeM J van den Bent, W Grisold, D Frappaz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor GroupR Stupp, A Tosoni, J E C Bromberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patientsJ Maringwa, C Quinten, M King, et al.
ESMO Open|November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14L Frehner, S Schär, S Hayoz, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
ESMO Open|April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]D König, S Schär, D Vuong, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|January 30, 2009
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapyJ L Lefebvre, F Rolland, M Tesselaar, et al.
Neurology|September 2, 2011
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastomaM Weller, T Gorlia, J G Cairncross, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2015
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trialN Fazio, R Biffi, R Maibach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2003
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiformeM J van den Bent, W Grisold, D Frappaz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor GroupR Stupp, A Tosoni, J E C Bromberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patientsJ Maringwa, C Quinten, M King, et al.
ESMO Open|November 11, 2025
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14L Frehner, S Schär, S Hayoz, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
ESMO Open|April 25, 2022
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]D König, S Schär, D Vuong, et al.
Pageof 8